NASDAQ:SYBX Synlogic (SYBX) Stock Price, News & Analysis $1.67 -0.01 (-0.60%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.59▼$1.6850-Day Range$1.43▼$1.7152-Week Range$1.35▼$8.85Volume1,895 shsAverage Volume72,878 shsMarket Capitalization$19.56 millionP/E RatioN/ADividend YieldN/APrice Target$65.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Synlogic alerts: Email Address Synlogic MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside3,792.2% Upside$65.00 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.48) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector588th out of 936 stocksPharmaceutical Preparations Industry270th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingSynlogic has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSynlogic has received no research coverage in the past 90 days.Read more about Synlogic's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the float of Synlogic has been sold short.Short Interest Ratio / Days to CoverSynlogic has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Synlogic has recently increased by 21.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYBX. Previous Next 1.8 News and Social Media Coverage News SentimentSynlogic has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Synlogic this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.01% of the stock of Synlogic is held by insiders.Percentage Held by Institutions63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Synlogic's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Synlogic are expected to grow in the coming year, from ($2.48) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Synlogic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Synlogic Stock (NASDAQ:SYBX)Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.Read More SYBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYBX Stock News HeadlinesJuly 21, 2024 | wsj.comSynlogic Inc.July 21, 2024 | morningstar.comSynlogic Inc SYBXJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...May 23, 2024 | investorplace.comThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 16, 2024 | markets.businessinsider.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 14, 2024 | investorplace.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | finanznachrichten.deSynlogic, Inc.: Synlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | baystreet.caSynlogic Flat on Q1 NumbersJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...May 14, 2024 | globenewswire.comSynlogic Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comWe Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth CarefullyApril 16, 2024 | finance.yahoo.comSynlogic, Inc. (SYBX)April 6, 2024 | investing.comSynlogic's head of finance sells shares worth $325March 21, 2024 | markets.businessinsider.comHold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic UncertaintiesMarch 19, 2024 | globenewswire.comSynlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 20, 2024 | finance.yahoo.comSynlogic Adopts Limited Duration Stockholders Rights PlanFebruary 20, 2024 | globenewswire.comSynlogic Adopts Limited Duration Stockholders Rights PlanFebruary 13, 2024 | markets.businessinsider.comHold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price TargetSee More Headlines Receive SYBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYBX CUSIPN/A CIK1527599 Webwww.synlogictx.com Phone(617) 401-9975Fax512-681-5201Employees6Year Founded2013Price Target and Rating Average Stock Price Target$65.00 High Stock Price Target$90.00 Low Stock Price Target$30.00 Potential Upside/Downside+3,792.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($10.0284) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,280,000.00 Net Margins-2,284.65% Pretax Margin-2,284.24% Return on Equity-189.99% Return on Assets-113.90% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$3.37 million Price / Sales5.80 Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.36Miscellaneous Outstanding Shares11,710,000Free Float10,769,000Market Cap$19.56 million OptionableNo Data Beta0.92 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Antoine Awad (Age 44)Principal Executive Officer Comp: $580.33kDr. Timothy K. Lu M.D. (Age 43)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. James J. Collins Ph.D. (Age 58)Co-Founder & Member of Scientific Advisory Board Ms. Mary Beth Dooley (Age 43)VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer Mr. Brendan St. AmantGeneral Counsel & Corporate SecretaryMr. Ajay MunshiVice President of Corporate DevelopmentMr. Adam J. ThomasChief People OfficerDr. Caroline B. Kurtz Ph.D.Chief Development OfficerMs. Molly Harper (Age 47)Chief Business Officer Dr. Neal Sondheimer M.D.Ph.D., VP & Head of ClinicalMore ExecutivesKey CompetitorsAllakosNASDAQ:ALLKEagle PharmaceuticalsNASDAQ:EGRXSpero TherapeuticsNASDAQ:SPROGeneluxNASDAQ:GNLXEyenoviaNASDAQ:EYENView All CompetitorsInsidersAntoine AwadSold 372 sharesTotal: $643.56 ($1.73/share)Mary Beth DooleySold 188 sharesTotal: $325.24 ($1.73/share)View All Insider Transactions SYBX Stock Analysis - Frequently Asked Questions How have SYBX shares performed this year? Synlogic's stock was trading at $3.85 on January 1st, 2024. Since then, SYBX shares have decreased by 56.6% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Synlogic's earnings last quarter? Synlogic, Inc. (NASDAQ:SYBX) posted its earnings results on Tuesday, May, 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.80) by $1.80. The biotechnology company had revenue of $0.01 million for the quarter. Synlogic had a negative trailing twelve-month return on equity of 189.99% and a negative net margin of 2,284.65%. When did Synlogic's stock split? Synlogic's stock reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Synlogic? Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:SYBX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.